ASCO® 2023 Insights: "Dr. Roy Herbst on ADAURA Trial OS Analysis of Adjuvant Osimertinib in Patients With Resected EGFRm Stage IB–IIIA NSCLC"

By ecancer FEATURING Roy Herbst
By ecancer FEATURING Roy Herbst
0 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login